Anti-BCMA CAR T Cell
Anti-BCMA CAR T Cell Uses, Dosage, Side Effects, Food Interaction and all others data.
Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal antibody like isatuximab.
Anti-BCMA CAR T Cell, also known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like axicabtagene ciloleucel and brexucabtagene autoleucel. These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen. The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain. Anti-BCMA CAR T Cell is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma.
Anti-BCMA CAR T Cell was granted FDA approval on 26 March 2021.
| Trade Name | Anti-BCMA CAR T Cell |
| Generic | Idecabtagene vicleucel |
| Idecabtagene vicleucel Other Names | Anti-BCMA CAR T cell, IDE-CEL, Idecabtagene vicleucel |
| Type | |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Anti-BCMA CAR T Cell is an autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma.
Anti-BCMA CAR T Cell is indicated to treat adult patients with relapsed or refractory multiple myeloma who have tried at least 4 other lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 monoclonal antibody.
Anti-BCMA CAR T Cell is also used to associated treatment for these conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma
How Anti-BCMA CAR T Cell works
Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.
The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain. The single chain variable fragment (scFv) allows for B-cell maturation antigen specificity of the CAR. The CD23ζ cytoplasmic domain mediates T-cell activation by CD2, a T-cell surface adhesion molecule. 4-1BB enhances cytotoxic T-cell activity as well as the production of interferon-γ.
Anti-BCMA CAR T Cell binds to B-cell maturation antigen expressing cells. Binding to the target leads to proliferation of idecabtagene vicleucel, secretion of cytokines, and lysis of the targeted cells.
Toxicity
Data regarding overdose of idecabtagene vicleucel is not readily available. However, patients experiencing an overdose may experience and increased risk and severity of adverse effects including cytokine release syndrome, infection, fatigue, and musculoskeletal pain. Patients should be treated with symptomatic and supportive measures.
Food Interaction
No interactions found.Elimination Route
Anti-BCMA CAR T Cell reaches a geometric mean Cmax of 256,333 copies/µg, with a median Tmax of 11 days, and a geometric mean AUC0-28 days of 3,088,455 days*copies/µg.
Innovators Monograph
You find simplified version here Anti-BCMA CAR T Cell
